Merck & Co., Inc. $MRK Shares Sold by Modera Wealth Management LLC
Modera Wealth Management LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 6.0% in Q2, now holding 45,255 shares valued at $3.58 million. Other investors also adjusted their holdings. Merck's stock opened at $86.34, with a market cap of $215.66 billion and a P/E ratio of 13.30. The company reported Q3 earnings of $2.58 EPS, exceeding estimates, with revenue of $17.28 billion. Analysts have mixed ratings on the stock, with price targets ranging from $90 to $95.
Modera Wealth Management LLC lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 6.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 45,255 shares of the company's stock after selling 2,910 shares during the quarter. Modera Wealth Management LLC's holdings in Merck & Co., Inc. were worth $3,582,000 at the end of the most recent quarter.
Get Merck & Co., Inc. alerts:
- 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
Other large investors have also modified their holdings of the company. Peoples Financial Services CORP. grew its stake in Merck & Co., Inc. by 0.5% during the 2nd quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company's stock valued at $1,803,000 after acquiring an additional 122 shares in the last quarter. McLean Asset Management Corp grew its position in shares of Merck & Co., Inc. by 3.7% in the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company's stock valued at $292,000 after purchasing an additional 125 shares in the last quarter. Cora Capital Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 2.4% in the second quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company's stock valued at $423,000 after purchasing an additional 125 shares during the last quarter. Saiph Capital LLC increased its holdings in shares of Merck & Co., Inc. by 3.7% in the first quarter. Saiph Capital LLC now owns 3,565 shares of the company's stock valued at $320,000 after purchasing an additional 128 shares during the last quarter. Finally, Physician Wealth Advisors Inc. lifted its position in Merck & Co., Inc. by 2.9% during the second quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company's stock worth $363,000 after buying an additional 128 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.
Merck & Co., Inc. Stock Performance
NYSE:MRK opened at $86.34 on Friday. The company has a fifty day simple moving average of $84.59 and a two-hundred day simple moving average of $82.04. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $105.07. The company has a market cap of $215.66 billion, a price-to-earnings ratio of 13.30, a price-to-earnings-growth ratio of 0.95 and a beta of 0.34.
- 5 Healthcare Plays Powering the Sector’s Big Comeback
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.36 by $0.22. The business had revenue of $17.28 billion during the quarter, compared to analysts' expectations of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business's quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have weighed in on MRK. Wells Fargo & Company lowered their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 30th. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "strong-buy" rating in a research report on Saturday. Citigroup initiated coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They issued a "neutral" rating and a $95.00 price objective for the company. Weiss Ratings restated a "hold (c-)" rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Finally, Berenberg Bank downgraded shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and reduced their target price for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $104.47.
- As the Market Rotates, This Healthcare ETF Is Leading the Way
Check Out Our Latest Stock Report on MRK
Insider Buying and Selling at Merck & Co., Inc.
In other news, EVP David Michael Williams sold 8,614 shares of the firm's stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $83.59, for a total value of $720,044.26. Following the sale, the executive vice president directly owned 24,578 shares in the company, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.13% of the company's stock.
Merck & Co., Inc. Company Profile
(Free Report)Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- 3 Small Caps With Big Return Potential
- OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever
- How is Compound Interest Calculated?
- 2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail
- What is a Special Dividend?
- CrowdStrike Partners With CoreWeave But Investors Sell the News
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Merck & Co., Inc. Right Now?
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
